TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06948318: A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia

Sponsor: Takeda · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT06948318 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06948318 Rescue Dossier →